BCT:CC News and Press, Briacell Therapeutics Corp.

A look at the top 10 most actives in Canada TC Energy Corporation (TRP) rose 0.2% to $53.5 on volume of 22,020,828 shares Fission Uranium Corp. (FCU) rose 0.0% to $1.19 on volume of 19,601,007 shares Victoria Gold Corp. (VGCX) fell 81.7% to $1.36 on volume of 15,148,780 shares Whitecap ...

A look at the top 10 most actives in Canada Fission Uranium Corp. (FCU) rose 17.8% to $1.19 on volume of 38,584,199 shares TC Energy Corporation (TRP) rose 1.3% to $53.39 on volume of 20,277,299 shares iShares S&P/TSX 60 Index ETF (XIU) rose 1.4% to $33.0001 on volume of 14,881,992 sh...

A look at the top 10 most actives in Canada Cenovus Energy Inc. (CVE) fell 0.9% to $25.51 on volume of 57,122,592 shares TC Energy Corporation (TRP) rose 0.9% to $52.71 on volume of 31,605,194 shares PrairieSky Royalty Ltd. (PSK) fell 4.7% to $25.89 on volume of 26,954,600 shares Canadi...

Crown Capital Partners Inc. (CRWN:CA) is expected to report for Q1 2024 Aberdeen International Inc. (AAB:CA) is expected to report for Q1 2025 Haivision Systems Inc. (HAI:CA) is expected to report for Q2 2024 Peyto Exploration & Development Corp. (PEY:CA) is expected to report $0....

A look at the top 10 most actives in Canada iShares S&P/TSX 60 Index ETF (XIU) fell 0.9% to $32.99 on volume of 8,426,543 shares Suncor Energy Inc. (SU) fell 1.3% to $51.83 on volume of 3,293,513 shares Pembina Pipeline Corporation (PPL) fell 1.0% to $50.79 on volume of 2,857,871 shar...

BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC) resistant patients Therapy well-tolerate...

PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...

Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq...

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastases Median progression free survival (PFS) of 4.1 months in ADC resistant patients - double the PFS of patients in similar studies 1,2,...

PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer car...